newsfilter
← Latest News
GlobeNewswire·

Jounce Therapeutics Reports First Quarter 2022 Financial Results

- Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 - - Target enrollment achieved in SELECT tria